Intravitreal Triamcinolone Acetonide Therapy in Diabetic Macular Edema - Evaluation of the Effects of Metabolic Control, Serum Inflammatory Markers and Endothelial Factors

Márcia S Queiroz*, Fábio P Saraiva¹, Roni C Preti¹, Rosa T Fukui¹, Walter Y Takahashi², Márcia Nery¹ and Maria Elizabeth R Silva¹ ³

¹Diabetes Unit, Endocrine Service of Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil
²Department of Ophthalmology, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil
³Laboratory of Medical Investigation, University of São Paulo Medical School, São Paulo, Brazil

Abstract

The exact pathogenesis of retinopathy in diabetic individuals is not yet fully understood, but may involve chronic low-grade inflammation and dysfunction of the vascular endothelium. Intravitreal Triamcinolone Acetonide (IVTA) has been considered safe and effective to treat diabetic macular edema. The aim of this study was to evaluate the short and long term effects of IVTA injection on serum factors associated with inflammation and endothelial dysfunction, on diabetes control, and the relationship of these markers with changes in visual acuity after IVTA therapy. This study involved 15 patients with type 2 diabetes evaluated at the Hospital das Clínicas of University of São Paulo medical school. The levels of C-reactive protein, fibrinogen, soluble intercellular adhesion molecule-1, interleukin-6, vascular endothelial growth factor, tumor necrosis factor-alpha, transforming growth factor-beta 1 and insulin-like growth factor-1 were assessed at baseline and after IVTA injection. The levels of serum factors associated with inflammation and endothelial dysfunction did not change significantly and were not correlated with grade of retinopathy or changes in macular edema and visual acuity after IVTA therapy. This study suggests that IVTA injections diabetic patients with retinopathy did not interfere with glucose control, blood inflammatory factors or markers of endothelial dysfunction.

Introduction

Proliferative Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME) are leading causes of blindness among working-age populations [1]. Advanced stages of DR are characterized by the growth of abnormal retinal blood vessels secondary to ischemia in an attempt to supply oxygenated blood to the hypoxic retina. Patients with diabetes can also develop DME at any time during the progression of DR, which involves retinal thickening in the macular area. DME occurs after breakdown of the Blood-Retinal Barrier (BRB) as a result of dilated hyper permeable capillary leakage and microaneurysms [2].

Several biochemical pathways have been proposed linking hyperglycemia and microvascular complications. These include accumulation of intracellular sorbitol, formation of Advanced Glycation End products (AGEs), oxidative stress, and activation of Protein Kinase C-β (PKC-β). These pathological pathways are thought to modulate the disease process through effects on cellular metabolism, signaling, and growth factors [3]. Inflammation and endothelial dysfunction are also mechanisms that may play an important role in the etiology of diabetic retinopathy. Increased levels of inflammation and endothelial dysfunction markers such as C-Reactive Protein (CRP), Fibrinogen (FIB), Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-α), Vascular Endothelial Growth Factors (VEGF), Growth Hormone, Insulin-like Growth Factor-1 (IGF-1), Transforming Growth Factor-β (TGF-β), soluble Intercellular Adhesion Molecule-1 (sICAM), and soluble Vascular Cell Adhesion Molecule-1 (sVCAM) [4-9] have been associated with development of microalbuminuria [10-12], which itself is strongly associated with retinopathy in type 1 and type 2 diabetes [13]. Also high levels of the 2 latter markers have been reported in subjects with retinopathy [8,9,14,15].

Opposite effects have been linked to corticosteroids which reduce the breakdown of the blood-retinal barrier, decrease inflammation, and down-regulate the production of vascular endothelial growth factor [16,17]. The use of Intravitreal Triamcinolone Acetonide (IVTA) has increased in the last 7 years after reports of successful treatment of macular edema secondary to diabetes, uveitis, and central retinal vein [10,18-22].

However, no study to date has reported the effects of IVTA on blood glucose and inflammatory marker levels or their relationship with improvements in macular edema. Our study is the first of its kind to report the short (7 days) and long term (30 days) effects of IVTA on diabetes control and on the serum factors associated with inflammation and endothelial dysfunction (CRP, fibrinogen, interleukin-6, sICAM, VEGF, TNF-α and TGF-β) and in type 2 diabetes patients with prevalent moderate or severe diabetic retinopathy.
Patients

This study involved 15 type 2 diabetes patients (9 men and 6 women) presenting diffuse macular edema, regularly attending the Ophthalmologic Service of Hospital das Clínicas of the São Paulo University medical school. All patients first underwent follow-up with a diabetes specialist for 2.3 ± 1.7 months until achieving metabolic control, characterized by fasting blood glucose levels < 150 mg/dL and HbA1c < 7.5%. Subsequently, the patients were evaluated and treated by a single fellowship-trained retina specialist. A full ocular examination including best corrected visual acuity, slit lamp biomicroscopy, tonometry, dilated ophthalmoscopy, and Optical Coherence Tomography (OCT; Stratus OCT™ model 3000, version 4.0.1, Carl zeiss Meditec Inc. Dublin, CA) was performed. Also, the level of retinopathy was graded as moderate or severe, proliferative or non proliferative, and the level of macular edema defined according to the early treatment diabetic retinopathy study [23].

The following exclusion criteria were adopted: chronic renal disease (serum creatinine > 1.5 mg/dl), uncontrolled arterial hypertension (PA > 150 × 90 mmHg), high blood glucose levels (fasting glucose > 150 mg/dl and HbA1c > 7.5%), and any severe concomitant illness. Patients using antihypertensive or lipid-lowering agents were not excluded, but the doses of these medications were kept stable throughout the study protocol. The study was approved by the Ethics Committee of Hospital das Clínicas of the University of São Paulo medical school and all participants gave written informed consent. Nine out of 15 patients were submitted to photocoagulation 3 to 4 months prior to IVTA treatment.

Methods

Patients' fasting serum was ascertained at three different times (baseline, and on days 7 and 30 after 4mg of IVTA) in order to assess the blood levels of C-Reactive Protein (CRP), fibrinogen, soluble Intercellular Adhesion Molecule-1 (sICAM-1), interleukin-6 (IL-6), Vascular Endothelial Growth Factor (VEGF), TNF alpha, TGF beta 1, Insulin-like Growth Factor-I (IGF-1), and to provide a biochemical profile.

HbA1c (normal range 4-6%) was determined in whole blood using ion-exchange High-Performance Liquid Chromatography (HPLC). Fibrinogen was determined by a functional method [24]. The Enzyme-Linked Immunosorbent Assay (ELISA) method was used to measure Interleukin-6 (IL-6), sICAM, VEGF, TNF-α and TNF-β (R&D Systems), while high sensitive CRP (Behring) and IGF-1 (Diagnostic Systems Laboratories, Inc. Webster, Texas) were measured by radioimmunoassay. Other biochemical analyses were carried out using commercial kits, as part of the routine assessment at the Central Laboratory of the Hospital das Clínicas.

Statistical Analyses

The Graph Pad Prism Program version 4.0 for personal computers was used for the statistical analysis. Results are presented as means ± SD, while changes in sICAM-1, TGF-α, TGF-β, fibrinogen, CRP, IL-6, VEGF, HbA1c, and glycemia from baseline to 7th and 30th day after 4 mg IVTA injections were compared using the one-way analysis of variance.

(ANOVA) followed by Bonferroni’s test or Bartlett's test. The unpaired t test was used to compare differences between moderate and severe non-proliferative DR groups for all inflammation and endothelial variables studied. A P value ≤ 0.05 was considered statistically significant.

Results

Severe non proliferative DR was present in 8 patients, and moderate non proliferative observed in another 7 subjects. Prior treatment with panretinal photocoagulation was noted in 9 individuals. The clinical characteristics and biochemical profile of the subjects are shown in table 1.

<table>
<thead>
<tr>
<th>Table 1: Clinical and biochemical characteristics of type 2 diabetes patients enrolled in the study.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Number of patients</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Gender (M/F)</td>
</tr>
<tr>
<td>Duration of diabetes (years)</td>
</tr>
<tr>
<td>Fasting glucose (mg/dL)</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL)</td>
</tr>
<tr>
<td>LDL cholesterol (mg/dL)</td>
</tr>
<tr>
<td>Triglyceride (mg/dL)</td>
</tr>
<tr>
<td>HbA1c</td>
</tr>
</tbody>
</table>

IVTA injection had no influence on metabolic parameters (fasting blood glucose, HbA1c, total-cholesterol, LDL-c and triglycerides levels), which remained similar at baseline, day 7 and day 30.

Fibrinogen levels were slightly lower 7 and 30 days after IVTA, but this difference did not reach statistical significance, p = 0.05 (Figure1).

**Figure 1:** Plasma fibrinogen levels at baseline, 7 days and 30 days after IVTA injection.

Fibrinogen: mg/dL; P = 0.05 for baseline versus 7 days (7d), and baseline versus 30 days (30d).

Levels of CRP, another marker of endothelial dysfunction, together with inflammatory markers -TNF-α, IL-6, sICAM-1, VEGF, TNF alpha, TGF beta 1, IGF-1 did not change short or long term after IVTA injection (Table 2).
Four out of nine patients submitted to photocoagulation associated with IVTA, experienced a 10 or more letter improvement in visual acuity (44%) 4 months after IVTA, while only 2 patients treated exclusively with IVTA presented this improvement (33%). The gain in visual acuity was maintained after 6 months of follow-up. There was also a substantial reduction in central macular thickness after 30 days of IVTA treatment, with thickness decreasing significantly from 0.356 ± 0.06 μm to 0.236 ± 0.05 μm in a group that was treated using previous photocoagulation plus IVTA, and from 0.352 ± 0.09 μm to 0.236 ± 0.04 μm in patients treated exclusively with IVTA.

However, none of the inflammatory and endothelial dysfunction markers analyzed were significantly correlated with level of retinopathy, previous photocoagulation procedure, IVTA injection, improvement in visual acuity or decrease in macular thickness (P > 0.05 for all analyses; data not shown).

### Discussion

This study evaluated the effect of intravitreal triamcinolone acetonide on diabetes control, levels of serum inflammatory factors and markers of endothelial dysfunction in patients with type 2 diabetes, and also the relationship of these markers with macular edema and improvement in visual acuity was also investigated.

As the mean elimination half-life of intravitreal triamcinolone was reported to be 18.6 days in non-vitrectomized patients [25], we analyzed the patients at 7 and 30 days after a single dose of IVTA, in order to evaluate acute and long term effects of the drug. No difference was demonstrated in metabolic parameters such as fasting glucose, total and LDL-cholesterol and HbA1c levels, highlighting that low levels of retinopathy, photocoagulation and IVTA at 1 month of follow-up, but these results did not correlate with previous photocoagulation nor IVTA therapy. Moreover, the levels of inflammatory markers VEGF, IGF-1, TGF-β, TNF-α, IL-6 and sICAM were not correlated with improvement in visual acuity after IVTA injection. Other studies have associated the increased sera levels of sVCAM with diabetic retinopathy [8] and nephropathy [15]. Doganay et al., [36] demonstrated that TNF-α level in the serum of patients with Proliferative Diabetic Retinopathy (PDR) was higher than in patients with Non-Proliferative Diabetic Retinopathy (NPDR), Non-Diabetic Retinopathy (NDR) and controls. Perhaps, we did not observe a graded level of these markers because only patients with severe retinal damage were included.

It has been suggested that hyperglycemia may lead to the activation of proinflammatory cytokines that are crucial for development and progression of retinopathy [37,38]. These cytokines are involved in BRB breakdown by opening tight junctions of retinal vascular endothelial cells and pigmented epithelial cells which participate in DME [39,40]. Decline in the elevated IL-6 levels in human peripheral monocytes of patients with poorly controlled DM has been demonstrated after normalization of plasma glucose [41]. However, circulating plasma VEGF concentrations were not strongly correlated with risk factor status or microvascular disease in type 1 diabetes in the EUCLID study [42]. Therefore, increased production of local VEGF and other endothelial or inflammatory markers in ocular fluid [5], not reflected by an increase in their levels circulating in plasma, could explain these discrepancies. Fibrinogen levels, related to inflammatory status and incidence of retinopathy [43,44], were slightly lower 7 days and 30 days after IVTA (p = 0.05), whereas C-reactive protein levels did not change.

Improvements in visual acuity, akin to those observed by other authors [45-47], were found in 4 patients submitted to photocoagulation and IVTA at 1 month of follow-up, but these results did not correlate with the level of inflammatory and endothelial markers or glycemic control.

It is likely that no significant change in the levels of these inflammatory markers was observed because the patients enrolled in this study had already reached good and stable metabolic control before IVTA treatment. Changes in serum concentrations of cytokines have been shown to be associated with long-term metabolic control parameters, such as HbA1c and fructosamine for glycemic control, and HDL cholesterol for triglyceride metabolism, and lipid peroxidation [48,49]. Chiarelli et al., [43] reported an increase in the elevated plasma VEGF level in diabetic children and adolescents with poor glycemic control (HbA1c > 10%) after 2 years of tight metabolic control (HbA1c < 7%), suggesting the possible influence of long-term glycemic control on this serum marker level. The mean level of HbA1c in our patients (6.6%) was very stable in adolescents with poor glycemic control (HbA1c > 10%) after 2 years of tight metabolic control (HbA1c < 7%), suggesting the possible influence of long-term glycemic control on this serum marker level. The mean level of HbA1c in our patients (6.6%) was very stable in adolescents with poor glycemic control (HbA1c > 10%) after 2 years of tight metabolic control (HbA1c < 7%), suggesting the possible influence of long-term glycemic control on this serum marker level. The mean level of HbA1c in our patients (6.6%) was very stable in adolescents with poor glycemic control (HbA1c > 10%) after 2 years of tight metabolic control (HbA1c < 7%), suggesting the possible influence of long-term glycemic control on this serum marker level. The mean level of HbA1c in our patients (6.6%) was very stable in adolescents with poor glycemic control (HbA1c > 10%) after 2 years of tight metabolic control (HbA1c < 7%), suggesting the possible influence of long-term glycemic control on this serum marker level. The mean level of HbA1c in our patients (6.6%) was very stable in adolescents with poor glycemic control (HbA1c > 10%) after 2 years of tight metabolic control (HbA1c < 7%), suggesting the possible influence of long-term glycemic control on this serum marker level. The mean level of HbA1c in our patients (6.6%) was very stable in adolescents with poor glycemic control (HbA1c > 10%) after 2 years of tight metabolic control (HbA1c < 7%), suggesting the possible influence of long-term glycemic control on this serum marker level.
cells, thereby contributing to improvement in visual acuity and reduced macular thickness [44]. The present study suggests that a 4 mg IVTA injection in type 2 diabetic patients with retinopathy did not interfere with glucose control, blood inflammatory factors or markers of endothelial dysfunction, and showed that this therapy was associated with improvement in visual acuity in 6 out of 15 type 2 diabetes patients.

References


